LinkedIn →

What FDA Inspectors Actually Look at When They Audit Medical Device Equipment Validation

RB
MEPSCo GAMP · Last updated:
FDA audit focus: a validated medical device fill and labeling production line in a cleanroom

FDA inspectors reviewing medical device equipment validation don’t start with your IQ/OQ/PQ binders. They start by watching your line run, asking your operators how they do the work, and then comparing what they see to what your documentation says. The gap between those two things is what generates 483 observations.

KEY TAKEAWAYS
  • Investigators compare what your line actually does to what your documentation says; the gap is what generates 483 observations.
  • The 2026 QMSR framework reorganized inspections into six quality-management-system areas, and management review, internal audit, and supplier audit records are now directly inspectable.
  • The six things they check: validation before production, operating within the qualified range, requalification after changes, documented acceptance activities, SOPs that match the floor, and CAPA closed with verified effectiveness.
  • The riskiest gap is SOPs that don’t match floor operations — an investigator sees it in the first 20 minutes without opening a document.

There’s a common assumption in medical device manufacturing that a completed IQ/OQ/PQ package equals audit readiness. You did the qualification. You have the documents. You’re covered.

FDA investigators don’t share that assumption. What they’re evaluating isn’t whether the documentation exists — it’s whether the documentation describes what actually happens on the floor. Those are different questions, and the answer to the second one often turns out to be different from the first.

Under the Quality Management System Regulation that took effect in February 2026, FDA’s inspection approach changed in specific ways that matter for manufacturers of consumable diagnostics, IVD equipment, and similar products. Understanding what investigators look for — and how they look for it — is the difference between an inspection that closes with no observations and one that generates a formal response obligation.

What Changed in February 2026

The old Quality System Inspection Technique (QSIT) organized inspections around four subsystems. The new framework under QMSR compliance program CP 7382.850 reorganizes inspections around six quality management system areas:

  • Change control
  • Design and development
  • Management oversight
  • Measurement, analysis, and improvement
  • Outsourcing and purchasing
  • Production and service provision

Equipment validation and documentation live primarily in “production and service provision” — but an investigator reviewing your production line will pull threads into change control (was the equipment ever modified?), design and development (does the process match the design validation?), and measurement analysis (are your acceptance criteria and monitoring data consistent?).

Two other changes matter more than the reorganization.

First, management review records, internal audit reports, and supplier audit documentation are now directly inspectable. FDA eliminated a longstanding policy protecting those documents. If your management reviews document problems with equipment performance without corresponding corrective actions, investigators can see that.

Second, investigators are now trained as ISO 13485 specialists. The technical depth of equipment-related questions has increased. An investigator who knows ISO 13485 Section 7.5 (production and service provision) in detail will ask different questions than one working from a general inspection checklist.

The Six Things Investigators Look for in Equipment Documentation

Based on the structure of QMSR inspections and the 483 observation patterns that have accumulated over the past few years, here’s what investigators actually examine when they pull an equipment file.

Whether the process was validated before production began. The FDA’s starting question for any piece of production equipment is: was this process validated? For a diagnostic manufacturer with equipment that was procured and installed without proper IQ/OQ/PQ documentation, that’s the first observation. But for most manufacturers who have done the qualification, the question shifts to whether the validation covers the process as it actually runs.

Whether equipment is operating within its qualified conditions. The OQ establishes a qualified range. An investigator comparing the OQ to actual production records is checking whether the equipment ever runs outside that range. If it does, the qualification doesn’t cover those conditions, and product made outside the qualified range has an unresolved status.

Whether modifications triggered requalification. Any change to production equipment — relocation, repair, component replacement, software update, process parameter change — should trigger a formal assessment of whether requalification is required. Investigators look for change control records that document the assessment. Missing change control for equipment modifications is one of the most common observations in this area.

Whether acceptance activities are documented. Under QMSR’s production and service provision area, incoming inspection, in-process testing, and finished device acceptance all require documented criteria and results. For equipment that outputs product, that means records of acceptance tests tied to the process validation parameters, not just general quality inspection records.

Whether SOPs match current operations. This one catches manufacturers who have been running their line correctly but updating their procedures informally. An investigator watching the line and reading the SOP simultaneously will identify steps that don’t match. If the operator does something differently than the SOP describes — even if their approach is correct — that’s an observation.

Whether CAPA is closed on equipment-related nonconformances. If an equipment issue was identified, logged as a nonconformance, and has an open CAPA, investigators will look at whether the CAPA is closed with verified effectiveness. CAPA deficiencies appear in more than 60% of FDA enforcement actions against medical device manufacturers, according to Complizen’s 2025 analysis of FDA warning letters for medical devices. A CAPA that was closed without evidence that the issue was resolved doesn’t help your inspection.

Stainless fill-finish machine with peristaltic pumps on a validated medical device production line

Why Process Validation Is a Warning Letter Category

Process validation failures appear in FDA’s top 5 violation categories for medical device manufacturers. The FY2024 warning letter data shows 47 letters issued, nearly double the 24 issued in FY2023 — with process validation among the recurring patterns.

The FDA’s position on process validation is specific: where the output of a manufacturing process can’t be fully verified by subsequent inspection and test, the process must be validated. For IVD and diagnostic manufacturers, that covers nearly everything that happens before the finished product can be tested — fill processes, assembly, reagent handling, packaging. Most of the production equipment on a diagnostic manufacturing line is in a process that requires validation.

What FDA investigators look for in process validation documentation isn’t complicated, but getting it right requires the engineering work to be done before the documentation is written:

The validation protocol has to specify the parameters being tested, the acceptance criteria, and the rationale for the ranges selected. Generic protocols that cover the equipment type but not the specific process don’t satisfy the requirement.

The executed records have to match the approved protocol. Any deviation from the protocol during execution has to be documented, assessed, and dispositioned.

The validation has to cover worst-case conditions, not convenient conditions. A fill line validated at nominal speed and volume doesn’t demonstrate what happens at the upper end of the production range.

When those elements are in place, an inspection of the process validation documentation is straightforward. When they’re not — when the protocol is generic, the execution records have undocumented deviations, or the conditions tested don’t cover actual production — the investigation is extended.

The Document Retrieval Problem

This doesn’t show up in guidance documents, but it matters in practice.

An FDA investigator requests an equipment file during an inspection. The company’s quality team goes to retrieve it. It takes 45 minutes to locate the IQ, because it’s in a different folder than the OQ and PQ. The trace matrix isn’t in the equipment file at all — it’s somewhere else. The PM records are partially in a paper log and partially in a digital system, and pulling the full history requires accessing both.

An investigator who has been waiting 45 minutes for a document hasn’t found a violation yet. But they’ve formed a view of how well-organized the quality system is. That view affects how deeply they look at everything else.

The 2026 QMSR compliance program explicitly includes FDA’s ability to issue remote document requests before or instead of on-site visits. That means a manufacturer may receive a documentation request before an inspector arrives on-site. How quickly and completely they can respond to that request signals something about the state of the quality system.

Equipment documentation that lives in a single organized file — with the URS, IQ, OQ, PQ, trace matrix, FAT report, SOPs, calibration records, and PM history all accessible — changes the character of an inspection. It demonstrates that the documentation system is organized, not that someone assembled a package for the audit.

How GAMP Documentation Prevents the Common Observations

The observations that show up in equipment-related 483s aren’t random. They follow the documentation gaps that were present at the time of qualification, and those gaps usually trace back to the front end of the procurement process.

A User Requirements Specification that was written correctly before the equipment was ordered sets the scope for the entire qualification. The IQ can only qualify what the URS specified. The OQ can only test the parameters the URS defined. The PQ can only run the conditions the OQ established. If the URS was incomplete, the rest of the package inherits those gaps.

The trace matrix is the audit trail. It shows that each URS requirement has a corresponding qualification test, and that each test maps back to a requirement. When an investigator wants to know whether a specific requirement was tested, the trace matrix is the answer. Without it, the investigator has to reconstruct the connection manually, which takes time and introduces uncertainty.

The 22 documents in MEPSCo’s GAMP package aren’t 22 independent documents. They’re a sequential record of engineering decisions and qualification activities, from the initial Customer Requirements Document through FAT execution through sustaining SOPs. Each document connects to the next. When the package is complete, an investigator reviewing it can follow the project from initial requirements through current production without gaps.

That’s what audit-ready equipment documentation looks like. It’s a story that holds together.

Installed and qualified process skid with gauges and controls in a medical device facility

What Manufacturers Miss in Pre-Inspection Preparation

Most manufacturers doing pre-inspection preparation focus on the same things: reviewing SOPs, running mock audits, training staff on how to respond to investigators. Those are useful.

The gap is usually in the equipment documentation itself, because equipment documentation typically hasn’t been reviewed since the qualification was completed. By the time an inspection happens, the SOPs may have drifted from the procedures, the equipment may have been modified or repaired without formal change assessment, and the calibration records may show gaps.

The meddeviceguide.com 2026 FDA inspection readiness guide for medical devices emphasizes that inspectors verify “the manufacturing process described in the submission matches actual operations.” That verification requires reviewing the equipment documentation against current operations — not against the original qualification package.

A pre-inspection review of equipment documentation should answer three questions. Does the equipment still operate within its qualified conditions? Do the SOPs reflect current operation? Are the calibration, PM, and maintenance records current and complete?

If the answer to any of those is no, the gap needs to be addressed before the inspection, not explained during it.

What the QMSR Risk Framework Means for Equipment Files

Under QMSR, investigators evaluate whether manufacturers use risk management and risk-based decision making throughout their quality systems. For equipment, that means the qualification approach should reflect the risk the equipment represents to product quality.

Higher risk equipment — a fill system for a diagnostic reagent, an assembly machine for a critical component — warrants more rigorous qualification scope, more extensive worst-case testing, and more detailed sustaining records than a low-risk utility piece of equipment. If an investigator reviews an equipment qualification and finds that a critical production piece was qualified with the same documentation depth as a secondary piece of equipment, that’s a quality decision that may require explanation.

Risk management records are now directly inspectable under QMSR. If the decision to limit qualification scope on a piece of equipment was based on a risk assessment, that assessment needs to be in the file. If it wasn’t documented, it didn’t happen.

Getting the Documentation in Order Before the Inspector Arrives

The good news about FDA equipment validation documentation is that the gaps are predictable. They follow specific patterns — missing requalification after equipment changes, SOPs that don’t match operations, qualification conditions that don’t cover actual production range, CAPA closed without verified effectiveness.

For diagnostic manufacturers who procured equipment without proper engineering support on the front end, the documentation may have been assembled to satisfy an obligation rather than to describe the project. That documentation will have gaps. The IQ may exist but the trace matrix may not. The OQ may cover the nominal operating point but not the full range. The SOPs may not have been updated since commissioning.

Fixing those gaps before an inspection is possible. It requires reviewing the existing documentation, identifying what’s missing or inconsistent, and either correcting the records or formally acknowledging the limitation and addressing it through the quality system.

What you can’t do is fix it during the inspection. The time for documentation work is before the investigator arrives, with enough lead time to close any CAPAs that get opened in the process.

If you’re not sure whether your equipment documentation would hold up to a QMSR-level inspection, a documentation review is the right starting point. Schedule a Manufacturing Automation Assessment with MEPSCo GAMP and we’ll start with where your equipment files actually stand.

Common Questions About FDA Audits and Equipment Validation Documentation

If our equipment was qualified under the old 21 CFR 820 framework, does the QMSR require us to redo the qualification?

No. FDA’s QMSR guidance is explicit that existing qualifications remain valid if the equipment and process haven’t materially changed. What QMSR changes is the inspection framework — how investigators approach the review, not what documentation was required at the time. The risk is that documentation assembled under older expectations may have gaps that a more technically rigorous inspector will identify. A gap assessment of existing equipment files against the QMSR production and service provision requirements is a reasonable pre-inspection step.

Our line has been running for two years without issues. FDA hasn’t visited. How concerned should we be about equipment documentation gaps?

FDA warning letter volume for medical device manufacturers doubled from FY2023 to FY2024 — 24 letters to 47. The enforcement pace hasn’t slowed. A clean production record without a quality system inspection doesn’t mean the documentation is adequate; it means the documentation hasn’t been reviewed by an inspector yet. The manufacturers who get warning letters generally didn’t know the gaps were there until an investigator found them. The time to fix equipment documentation is before an inspection, not during one.

We purchased equipment from a vendor who provided the IQ/OQ/PQ documentation. Is that acceptable?

Vendor-provided documentation is a starting point, not a complete qualification package. The vendor documents the equipment as designed and built in their facility. Your qualification needs to document the equipment as installed and operating in your facility, running your specific product under your specific process conditions. Vendor IQ documents typically cover mechanical installation. You still need to execute and document the OQ and PQ against your own process parameters, and those parameters need to come from your URS.

What’s the riskiest documentation gap to have when an FDA investigator arrives?

A mismatch between your SOPs and actual floor operations — because that’s visible without reviewing any documents. An investigator watching your line and reading your SOP simultaneously will identify the gap in the first 20 minutes of the inspection. Every other documentation gap requires the investigator to find it in a document. This one finds itself. SOPs that accurately describe current operations, updated through formal change control whenever the process changes, are the most basic audit readiness requirement.

How often should equipment qualification documentation be reviewed after the initial qualification?

Annually at minimum, and any time the equipment is modified, relocated, repaired, or used for a new product or process. The calibration schedule is the simplest check — if the calibration certificate for a production-critical instrument is more than a year old, the equipment’s calibrated state is unverified. Beyond calibration, a periodic review should confirm that the SOPs match operations, that no undocumented deviations have occurred, and that the equipment’s physical condition still matches its qualified state.

Related reading

The Bottom Line

An FDA inspection of equipment validation isn’t a document check — it’s a comparison between what your line actually does and what your records say it does. The gaps that generate 483 observations are predictable, and they’re fixable before an inspector arrives, not during.

The highest-value pre-inspection work is a review of the equipment documentation itself — URS through IQ/OQ/PQ, trace matrix, change control, calibration and PM — against how the line runs today.

Reza Bashar at MEPSCo GAMP works with IVD and medical device manufacturers on equipment qualification and audit-ready documentation. If you want to know whether your equipment files would hold up to a QMSR-level inspection, reach out directly.